MA27605A1 - Dérivés de morpholine destinés à être utilisés comme agonistes de la dopamine dans le traitement d'un dysfonctionnement sexuel - Google Patents

Dérivés de morpholine destinés à être utilisés comme agonistes de la dopamine dans le traitement d'un dysfonctionnement sexuel

Info

Publication number
MA27605A1
MA27605A1 MA28324A MA28324A MA27605A1 MA 27605 A1 MA27605 A1 MA 27605A1 MA 28324 A MA28324 A MA 28324A MA 28324 A MA28324 A MA 28324A MA 27605 A1 MA27605 A1 MA 27605A1
Authority
MA
Morocco
Prior art keywords
chosen
group
treatment
sexual dysfunction
dopamine agonists
Prior art date
Application number
MA28324A
Other languages
English (en)
Inventor
Charlotte Moira Norfo Allerton
Andrew Douglas Baxter
Andrew Simon Cook
David Hepworth
Stephen Kwok-Fung Wong
Original Assignee
Pfizer
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GB0228787A external-priority patent/GB0228787D0/en
Priority claimed from GB0308460A external-priority patent/GB0308460D0/en
Priority claimed from GB0313606A external-priority patent/GB0313606D0/en
Application filed by Pfizer filed Critical Pfizer
Publication of MA27605A1 publication Critical patent/MA27605A1/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D265/00—Heterocyclic compounds containing six-membered rings having one nitrogen atom and one oxygen atom as the only ring hetero atoms
    • C07D265/28—1,4-Oxazines; Hydrogenated 1,4-oxazines
    • C07D265/30—1,4-Oxazines; Hydrogenated 1,4-oxazines not condensed with other rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/14—Drugs for dermatological disorders for baldness or alopecia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Psychiatry (AREA)
  • Reproductive Health (AREA)
  • Endocrinology (AREA)
  • Cardiology (AREA)
  • Pain & Pain Management (AREA)
  • Gynecology & Obstetrics (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Obesity (AREA)
  • Hospice & Palliative Care (AREA)
  • Addiction (AREA)
  • Anesthesiology (AREA)
  • Psychology (AREA)
  • Dermatology (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Child & Adolescent Psychology (AREA)
  • Pregnancy & Childbirth (AREA)
  • Nutrition Science (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

Dérivés de morpholine destinés à être utilisés comme agonistes de la dopamine dans le traitement d'un dysfonctionnement sexuel La présente invention propose des composés de formules (I), (Ia) et (Ib) dans lesquelles: A est choisi entre C-X et N, B est choisi entre C-Y et N, R1 est choisi entre H et un groupe alkyle en C1 à C6, R2 est choisi entre H et un groupe alkyle en C1 à C6, X est choisi entre H, des groupes HO, C(O)NH2, NH2, Y est choisi entre H, des groupes HO, NH2, Br, C1 et F, Z est choisi entre H, des groupes HO, F, CONH2 et CN; et leurs sels, produits de solvatation et précurseurs médicamenteux pharmaceutiquement acceptables; sous les réserves suivantes: pour un composé de formule (I), (Ia) ou (Ib), lorsque A représente un groupe C-X, B représente un groupe C-Y, au moins un de X, Y et Z doit représenter un groupe OH; pour un composé de formule (I), lorsque A représente un groupe C-X et B représente un groupe C-Y, Y représente H, Z représente H, R1 représente H et R2 représente H, alors X ne peut représenter un groupe OH; ces composés sont utiles comme agonistes de la dopanine pour le traitement, entre autres, d'un dysfonctionnement sexuel.
MA28324A 2002-12-10 2005-06-10 Dérivés de morpholine destinés à être utilisés comme agonistes de la dopamine dans le traitement d'un dysfonctionnement sexuel MA27605A1 (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GB0228787A GB0228787D0 (en) 2002-12-10 2002-12-10 Morpholine dopamine agonists
GB0308460A GB0308460D0 (en) 2003-04-11 2003-04-11 Morpholine dopamine agonists
GB0313606A GB0313606D0 (en) 2003-06-12 2003-06-12 Morpholine dopamine agonists

Publications (1)

Publication Number Publication Date
MA27605A1 true MA27605A1 (fr) 2005-11-01

Family

ID=32512061

Family Applications (1)

Application Number Title Priority Date Filing Date
MA28324A MA27605A1 (fr) 2002-12-10 2005-06-10 Dérivés de morpholine destinés à être utilisés comme agonistes de la dopamine dans le traitement d'un dysfonctionnement sexuel

Country Status (37)

Country Link
EP (1) EP1572214B1 (fr)
JP (3) JP3889775B2 (fr)
KR (1) KR100796102B1 (fr)
AP (1) AP2005003325A0 (fr)
AR (1) AR042339A1 (fr)
AT (1) ATE460938T1 (fr)
AU (1) AU2003302878B2 (fr)
CA (1) CA2508262C (fr)
CO (1) CO5700781A2 (fr)
CR (1) CR7869A (fr)
CY (1) CY1110130T1 (fr)
DE (1) DE60331769D1 (fr)
DK (1) DK1572214T3 (fr)
EA (1) EA009589B1 (fr)
EC (1) ECSP055850A (fr)
ES (1) ES2339767T3 (fr)
GE (1) GEP20074272B (fr)
HK (1) HK1081850A1 (fr)
HN (1) HN2003000401A (fr)
HR (1) HRP20050523A2 (fr)
IS (1) IS7843A (fr)
MA (1) MA27605A1 (fr)
MX (1) MXPA05006151A (fr)
MY (1) MY144338A (fr)
NL (1) NL1024983C2 (fr)
NO (1) NO330143B1 (fr)
NZ (1) NZ540505A (fr)
OA (1) OA13014A (fr)
PA (1) PA8591601A1 (fr)
PE (1) PE20040906A1 (fr)
PL (1) PL377480A1 (fr)
PT (1) PT1572214E (fr)
RS (1) RS51442B (fr)
SI (1) SI1572214T1 (fr)
TW (1) TW200423944A (fr)
UY (1) UY28117A1 (fr)
WO (1) WO2004052372A1 (fr)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EA200601985A1 (ru) * 2004-05-26 2007-04-27 Пфайзер Лимитед Новые производные индазола и индолона и их применение в качестве фармацевтических средств
JP4198183B2 (ja) * 2004-05-27 2008-12-17 ファイザー・インク 選択的ドーパミンｄ３アゴニストとしてのアミノピリジン誘導体
GB0502509D0 (en) * 2005-02-07 2005-03-16 Pfizer Ltd Novel salt form of a dopamine agonist
TW200740779A (en) 2005-07-22 2007-11-01 Mitsubishi Pharma Corp Intermediate compound for synthesizing pharmaceutical agent and production method thereof
GB0700786D0 (en) * 2007-01-15 2007-02-21 Pfizer Ltd Morpholine dopamine agonists for the treatment of pain
JP5952267B2 (ja) 2010-05-21 2016-07-13 リサーチ・トライアングル・インスティチュート 薬物依存を処置するためのヒドロキシブプロピオン類似体（政府支援研究または開発）
CA2800220C (fr) * 2010-05-21 2019-04-30 Research Triangle Institute Phenylmorpholines et leurs analogues
CA2932003A1 (fr) * 2013-12-11 2015-06-18 F. Hoffmann-La Roche Ag Procede de preparation de 2-arylmorpholines chirales
GB2543296A (en) 2015-10-13 2017-04-19 Indivior Uk Ltd Dopamine D3 receptor antagonists having a morpholine moiety
EP3725768A1 (fr) * 2019-04-17 2020-10-21 Newron Pharmaceuticals S.p.A. Procédé de production de dérivés de 2-[2-(phényl)éthylamino]alkanéamide

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB851311A (en) * 1958-04-02 1960-10-12 Geigy Ag J R Morpholine compounds and their production
GB9108629D0 (en) * 1991-04-23 1991-06-12 Wellcome Found Heterocyclic pharmaceutical compounds,preparation and use
GB0130219D0 (en) * 2001-12-18 2002-02-06 Pfizer Ltd Compounds for the treatment of sexual dysfunction

Also Published As

Publication number Publication date
AU2003302878B2 (en) 2009-04-23
NO20052557D0 (no) 2005-05-26
AP2005003325A0 (en) 2005-06-30
WO2004052372A1 (fr) 2004-06-24
JP3920908B2 (ja) 2007-05-30
GEP20074272B (en) 2007-12-25
NO20052557L (no) 2005-09-06
TW200423944A (en) 2004-11-16
RS51442B (en) 2011-04-30
UY28117A1 (es) 2004-07-30
ATE460938T1 (de) 2010-04-15
PL377480A1 (pl) 2006-02-06
PE20040906A1 (es) 2005-01-24
OA13014A (en) 2006-11-10
KR100796102B1 (ko) 2008-01-21
KR20050094813A (ko) 2005-09-28
MXPA05006151A (es) 2005-08-26
IS7843A (is) 2005-05-12
NL1024983C2 (nl) 2005-02-01
NO330143B1 (no) 2011-02-21
DE60331769D1 (de) 2010-04-29
HRP20050523A2 (en) 2005-08-31
EP1572214A1 (fr) 2005-09-14
JP2006511599A (ja) 2006-04-06
PT1572214E (pt) 2010-05-06
EA009589B1 (ru) 2008-02-28
JP4624341B2 (ja) 2011-02-02
EP1572214B1 (fr) 2010-03-17
ECSP055850A (es) 2005-09-20
CA2508262A1 (fr) 2004-06-24
NZ540505A (en) 2007-02-23
CR7869A (es) 2005-07-08
EA200500801A1 (ru) 2005-12-29
SI1572214T1 (sl) 2010-07-30
CY1110130T1 (el) 2015-01-14
JP3889775B2 (ja) 2007-03-07
CO5700781A2 (es) 2006-11-30
DK1572214T3 (da) 2010-06-07
JP2006232857A (ja) 2006-09-07
PA8591601A1 (es) 2004-12-16
JP2007084575A (ja) 2007-04-05
AR042339A1 (es) 2005-06-15
RS20050445A (en) 2007-04-10
MY144338A (en) 2011-08-29
HN2003000401A (es) 2004-11-23
HK1081850A1 (en) 2006-05-26
CA2508262C (fr) 2009-12-01
AU2003302878A1 (en) 2004-06-30
ES2339767T3 (es) 2010-05-25
NL1024983A1 (nl) 2004-06-11

Similar Documents

Publication Publication Date Title
MA27605A1 (fr) Dérivés de morpholine destinés à être utilisés comme agonistes de la dopamine dans le traitement d'un dysfonctionnement sexuel
MA28747B1 (fr) Dérivés de pyridine
CA2530006A1 (fr) Inhibiteurs de la beta-secretase de phenylcarboxylate destines au traitement de la maladie d'alzheimer
RU2214398C2 (ru) Производное циклоалкена, способ его получения (варианты), фармацевтическая композиция, способ ингибирования, способ профилактики или лечения
MA27774A1 (fr) Inhibiteurs de phosphatidylinositol 3-kinase
MA29926B1 (fr) Derives de pyrazine
MA31419B1 (fr) Derives de pyridine
TNSN07349A1 (fr) Derives de n-(n-sulfonylaminomethyl) cyclopropanecarboxamide utiles pour le traitement de la douleur
MA26952A1 (fr) Derives d'imidazole a noyau aryle ou heteroaryle condense, utiles comme agents anti-inflammatoires et analgesiques.
TNSN07275A1 (fr) Derives de triazole substitues, servant d'antagonistes d'ocytocine
HUP0203700A2 (hu) N-szubsztituált cianopirrolidinek és cukorbetegség-ellenes szerként való alkalmazásuk és az ezeket tartalmazó gyógyászati készítmények
LU92602I2 (fr) Trametinib, optionnellement sous la forme d'un sel, hydrate ou solvate pharmaceutiquement acceptablede celui-ci
WO2005012269A8 (fr) Nouveau compose azole
MA31311B1 (fr) Dérivés d'indazole substitués par oxadiazole, destinés à être utilisés comme agonistes de la sphingosine 1-phosphate (s1p)
MA27560A1 (fr) Nouveaux derives de fluorglycoside heterocycliques, produits pharmaceutiques contenant ces composes et leur utilisation
MA27389A1 (fr) Derives de benzimidazole nouveaux utiles comme agents antiproliferatifs.
JP2004517087A5 (fr)
MA30014B1 (fr) Derives spirocycliques
MA26857A1 (fr) Azaindoles
TNSN05073A1 (fr) Quinazolinones spirocondensees nouvelles et leur utilisation comme inhibiteurs de phosphodiesterase
CA2571347A1 (fr) Derives de piperazine utilises dans le traitement de troubles sexuels feminins
MA32563B1 (fr) Dabigatran pour cathétérisme cardiaque de chirurgie percutanée
RU2000125568A (ru) Производные циклоалкенов, их получение и применение
MA31873B1 (fr) Inhibiteurs de la peptide déformylase
TNSN07145A1 (fr) Derives de 2-amido-4-phenylthiazole, leur preparation et leur application en therapeutique